Summary

Eligibility
for people ages 18-85 (full criteria)
Location
at UC Davis
Dates
study started
estimated completion
Principal Investigator
by Emanual Maverakis, MD (ucdavis)

Description

Summary

The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.

Keywords

Actinic Keratoses imiquimod aldara Keratosis, Actinic Keratosis

Eligibility

You can join if…

Open to people ages 18-85

  • Individuals between 18 to 85 years of age
  • Patients with a diagnosis that will result in treatment with imiquimod as standard of care, specifically actinic keratosis

You CAN'T join if...

  • Younger than 18 years or older than 85 years.
  • History of hypersensitivity/ allergic reaction or adverse reaction to imiquimod
  • Individuals with a diagnostic biopsy and supportive histology of a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).
  • Individuals with autoantibodies plus objective evidence of end organ damage related to a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).
  • Individuals with a history of serious infection within the last 6 months.
  • Individuals with tuberculosis, HIV, or hepatitis B, or C.
  • Patients unable to provide consent
  • Incarcerated individuals

Location

  • University of California Davis accepting new patients
    Sacramento California 95816 United States

Lead Scientist at University of California Health

  • Emanual Maverakis, MD (ucdavis)
    Professor, Dermatology. Authored (or co-authored) 165 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
ID
NCT04809662
Study Type
Observational
Last Updated